G2GBIO, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name G2GBIO, Inc.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 16.1%
- Equity ratio
- 86.1%
- ROE
- -20.7%
- Op. margin
- -2,884.2%
- Rev. growth
- -45.0%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | n/a | -205.7% | n/a | -20,562.6% | n/a |
| FY2022 separate | n/a | -119.3% | n/a | -42,559.7% | -25.2% |
| FY2023 separate | n/a | -121.4% | n/a | -1,776.7% | 2,693.5% |
| FY2024 separate | n/a | -471.6% | n/a | -1,399.8% | 3.9% |
| FY2025 separate | 16.1% | 86.1% | -20.7% | -2,884.2% | -45.0% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩35.4M | ₩26.5M | ₩739.8M | ₩768.9M | ₩423.1M |
| Operating profit | -₩7.3B | -₩11.3B | -₩13.1B | -₩10.8B | -₩12.2B |
| Pre-tax income | -₩31.1B | ₩15.1B | -₩10.5B | -₩83.3B | -₩12.1B |
| Net income | -₩31.1B | ₩15.1B | -₩10.5B | -₩83.3B | -₩12.1B |
| Total assets | ₩22.4B | ₩25.1B | ₩31.5B | ₩25.3B | ₩67.7B |
| Total liabilities | ₩68.4B | ₩55.1B | ₩69.8B | ₩144.9B | ₩9.4B |
| Total equity | -₩46.0B | -₩30.0B | -₩38.3B | -₩119.5B | ₩58.3B |
| Paid-in capital | ₩663.9M | ₩666.4M | ₩698.4M | ₩744.3M | ₩8.2B |
| Debt/equity (source value) | 0.0% | 0.0% | 0.0% | 100.0% | 16.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2017-03-22
- Listed
- 25/08/14
- Employees
- 48
- Auditor
- 신우회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1601110451528
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 지투지바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.